JP2022550221A5 - - Google Patents
Info
- Publication number
- JP2022550221A5 JP2022550221A5 JP2022544867A JP2022544867A JP2022550221A5 JP 2022550221 A5 JP2022550221 A5 JP 2022550221A5 JP 2022544867 A JP2022544867 A JP 2022544867A JP 2022544867 A JP2022544867 A JP 2022544867A JP 2022550221 A5 JP2022550221 A5 JP 2022550221A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- pharmaceutical composition
- alkyl
- composition according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019903681 | 2019-09-30 | ||
| AU2019903681A AU2019903681A0 (en) | 2019-09-30 | Medicinal cognitive treatments | |
| PCT/AU2020/051043 WO2021062472A1 (en) | 2019-09-30 | 2020-09-30 | Medicinal cognitive treatments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026077047A Division JP2026133451A (ja) | 2019-09-30 | 2026-05-01 | 認知機能の薬物治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022550221A JP2022550221A (ja) | 2022-11-30 |
| JP2022550221A5 true JP2022550221A5 (enExample) | 2023-10-10 |
Family
ID=75336310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544867A Pending JP2022550221A (ja) | 2019-09-30 | 2020-09-30 | 認知機能の薬物治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230000843A1 (enExample) |
| EP (1) | EP4037684A4 (enExample) |
| JP (1) | JP2022550221A (enExample) |
| KR (1) | KR20220080116A (enExample) |
| CN (1) | CN114761005A (enExample) |
| AU (1) | AU2020359291B2 (enExample) |
| CA (1) | CA3152902A1 (enExample) |
| CL (1) | CL2022000781A1 (enExample) |
| IL (1) | IL292739B2 (enExample) |
| MX (1) | MX2022003845A (enExample) |
| WO (1) | WO2021062472A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI855081B (zh) * | 2019-05-24 | 2024-09-11 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| IL303170A (en) * | 2020-11-25 | 2023-07-01 | Sage Therapeutics Inc | 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders |
| WO2024073794A1 (en) * | 2022-10-07 | 2024-04-11 | Actinogen Medical Limited | SUBJECT SELECTION FOR 11β-HSD1 INHIBITOR TREATMENT |
| CN121969372A (zh) * | 2023-10-03 | 2026-05-01 | 射线质医疗有限公司 | 片剂制剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2477983T3 (en) * | 2009-09-16 | 2015-06-29 | Univ Edinburgh | (4-phenyl-piperidin-1-yl) - [5-1H-pyrazol-4-yl) -thiophene-3-yl] -METHANONFORBINDELSER AND THEIR USE |
| BR112012027640B1 (pt) * | 2010-04-29 | 2021-08-03 | The University Of Edinburgh | Composto, composição farmacêutica, e, métodos de preparar uma composição farmacêutica, de inibir a função da 11beta-hidroxiesteroide desidrogenase do tipo 1 |
-
2020
- 2020-09-30 EP EP20870933.7A patent/EP4037684A4/en active Pending
- 2020-09-30 AU AU2020359291A patent/AU2020359291B2/en active Active
- 2020-09-30 JP JP2022544867A patent/JP2022550221A/ja active Pending
- 2020-09-30 CA CA3152902A patent/CA3152902A1/en active Pending
- 2020-09-30 CN CN202080082617.6A patent/CN114761005A/zh active Pending
- 2020-09-30 US US17/764,922 patent/US20230000843A1/en active Pending
- 2020-09-30 WO PCT/AU2020/051043 patent/WO2021062472A1/en not_active Ceased
- 2020-09-30 KR KR1020227014330A patent/KR20220080116A/ko not_active Ceased
- 2020-09-30 MX MX2022003845A patent/MX2022003845A/es unknown
-
2022
- 2022-03-29 CL CL2022000781A patent/CL2022000781A1/es unknown
- 2022-05-03 IL IL292739A patent/IL292739B2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2376172T3 (es) | Compuestos, formulaciones y métodos para tratar o prevenir la ros�?cea. | |
| KR0139626B1 (ko) | 강심제 | |
| JP2016534063A5 (enExample) | ||
| KR20160093000A (ko) | 창자 과투과성을 치료하기 위한 티로신 하이드록실라제 억제제 | |
| DE102010013716A1 (de) | Verwendung von Cytohesin-Inhibitoren | |
| JP2020529995A (ja) | 行動の変化の治療方法 | |
| EA030589B1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
| JP2022550221A (ja) | 認知機能の薬物治療 | |
| JP4246997B2 (ja) | 糖尿病由来虚血性心疾患の治療及び／または予防剤 | |
| BRPI0610574A2 (pt) | uso de um inibidor de quinase para receptor do fator de crescimento epidérmico (egfr) em pacientes resistentes a gefitinib | |
| WO2022026645A1 (en) | Treatment of acute respiratory distress syndrome (ards) | |
| US8716292B2 (en) | Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity | |
| JP2024509267A (ja) | リボソーム障害に関連する貧血を処置するための組成物および方法 | |
| JP2021503448A5 (enExample) | ||
| CN115702143A (zh) | 治疗系统性硬化症的方法 | |
| CN1859846A (zh) | 白屈菜赤碱、其类似物及其在治疗躁郁症和其他认知紊乱中的应用 | |
| AU2017204652B2 (en) | Treatment of Type I and Type II diabetes | |
| CA2684174A1 (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson | |
| JP2021503010A5 (enExample) | ||
| RU2005136426A (ru) | 5-гидроксииндолы с пиридин-n-оксидными группами и их применение в качестве ингибиторов фосфодиэстеразы 4 | |
| JP6907174B2 (ja) | アミロイド線維形成の抑制又は阻害剤 | |
| WO2011030575A1 (ja) | 慢性疼痛治療剤 | |
| JP2013530937A (ja) | 自己免疫疾患の処置剤 | |
| JP2025518700A (ja) | グリシン輸送阻害剤を用いて肝性ポルフィリン症を処置するための組成物および方法 | |
| WO2026064696A1 (en) | Compositions and methods for treating myelodysplastic syndrome with glycine transport inhibitors |